Analyze whether Teclistamab has been officially launched

Teritusumab (Teclistamab-cqyv) is anIgG4-PAA bispecific antibody that can simultaneously target T CD3 receptors on the cell surface and BCMA (B cell maturation antigen) expressed on multiple myeloma (MM) cells. This unique dual-targeting mechanism enables it to directly activate T cells to recognize and kill tumor cells, creating a new situation in the treatment of multiple myeloma. As the world's first approved bispecific antibody against BCMA, the launch of teritusumab marks an important development in the field of immunotherapy.

In the international market, teritusumab received conditional marketing authorization from the European Commission for the first time in August 2022. This means that the drug can be used to treat patients with multiple myeloma under specific conditions in the EU, and its efficacy and safety will be further verified through subsequent clinical data. In October of the same year, the US FDA granted it accelerated approval for the treatment of multiple myeloma patients who have received multiple lines of therapy but whose disease is still active. The accelerated approval reflects its significant clinical efficacy and urgent need, providing new treatment opportunities for patients whose conditions cannot be controlled by traditional treatments.

In China, teritusumab was officially approved in June 2024, with the trade name Telicat. This means that domestic patients can obtain the drug through formal channels, but it is not yet included in medical insurance. Therefore, despite the availability of drugs, financial burden remains an important factor that patients must consider in treatment selection. At the same time, because it is an innovative biological agent, domestic medical institutions usually need to provide professional injection and monitoring services to ensure the safety and effectiveness of treatment.

Overall, teritusumab has been officially launched globally and has been approved by regulatory agencies in many countries. Its innovative bispecific antibody mechanism gives it unique advantages in the treatment of multiple myeloma. Although it is already on the market in China, it is not included in medical insurance. Patients need to weigh drug efficacy, economic burden and medical conditions when choosing a treatment plan.

Reference materials:https://go.drugbank.com/drugs/DB16655